| Non-Small Cell Lung Carcinoma

Alunbrig vs Tafinlar + Mekinist

Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.
Deep comparison between: Alunbrig vs Tafinlar with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsTafinlar has a higher rate of injection site reactions vs Alunbrig based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tafinlar but not Alunbrig, including UnitedHealthcare
Sign up to reveal the full AI analysis
Alunbrig
Tafinlar
At A Glance
Oral
Once daily
ALK inhibitor
Oral
Twice daily
BRAF kinase inhibitor
Indications
  • Non-Small Cell Lung Carcinoma
  • melanoma
  • Non-Small Cell Lung Carcinoma
  • Anaplastic thyroid carcinoma
  • Low grade glioma
  • Solid Neoplasm
Dosing
Non-Small Cell Lung Carcinoma 90 mg orally once daily for the first 7 days; then increase to 180 mg orally once daily; may be taken with or without food.
Melanoma 150 mg orally twice daily as single agent or in combination with trametinib 2 mg once daily, oral route.
Non-Small Cell Lung Carcinoma 150 mg orally twice daily in combination with trametinib 2 mg once daily, oral route.
Anaplastic thyroid carcinoma 150 mg orally twice daily in combination with trametinib 2 mg once daily, oral route.
Low grade glioma Weight-based dosing in pediatric patients (20-150 mg twice daily) in combination with trametinib, oral route.
Solid Neoplasm 150 mg orally twice daily in combination with trametinib 2 mg once daily in adults; weight-based dosing in pediatric patients >= 1 year, oral route.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) diarrhea, nausea, rash, cough, hypertension, fatigue, myalgia, headache, dyspnea, back pain, pruritus, edema, pyrexia, dizziness, pneumonia, arthralgia, constipation, bradycardia, abdominal pain, upper respiratory tract infection, peripheral neuropathy, stomatitis, vomiting, increased blood cholesterol
Serious ILD/pneumonitis, hypertension, bradycardia, visual disturbance, CPK elevation, pancreatic enzyme elevation, hepatotoxicity, hyperglycemia, photosensitivity
Most common (>= 20%) Pyrexia, rash, hyperkeratosis, headache, arthralgia, papilloma, alopecia, palmar-plantar erythrodysesthesia syndrome, chills, cough, nausea, vomiting, diarrhea, fatigue, dry skin, myalgia, constipation, decreased appetite, edema, hemorrhage, dyspnea, musculoskeletal pain, abdominal pain, epistaxis, dermatitis acneiform
Serious New primary malignancies (cutaneous and non-cutaneous RAS mutation-positive), hemorrhage, cardiomyopathy, uveitis, serious febrile reactions, serious skin toxicities including SCAR, hyperglycemia, glucose-6-phosphate dehydrogenase deficiency, hemophagocytic lymphohistiocytosis
Pharmacology
Brigatinib is a tyrosine kinase inhibitor (TKI) with activity against ALK, ROS1, IGF-1R, FLT-3, and EGFR deletion and point mutations, inhibiting ALK autophosphorylation and downstream signaling proteins (STAT3, AKT, ERK1/2, S6) in ALK-positive NSCLC cell lines and xenograft models.
Dabrafenib is a BRAF kinase inhibitor that targets mutated BRAF V600E, V600K, and V600D enzymes, inhibiting cell growth in BRAF V600 mutation-positive tumors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Alunbrig
  • Covered on 5 commercial plans
  • PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
View full coverage details ›
Tafinlar
  • Covered on 5 commercial plans
  • PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
View full coverage details ›
UnitedHealthcare
Alunbrig
  • Covered on 4 commercial plans
  • PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
View full coverage details ›
Tafinlar
  • Covered on 4 commercial plans
  • PA (6/8) · Step Therapy (4/8) · Qty limit (1/8)
View full coverage details ›
Humana
Alunbrig
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
View full coverage details ›
Tafinlar
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/momo
Alunbrig SMART Free Trial Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Tafinlar.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
AlunbrigView full Alunbrig profile
TafinlarView full Tafinlar profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.